Compare BioNano Genomics Inc (BNGO) vs Mattel Inc (MAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Mattel Inc — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while Mattel Inc trades at $13.99 (market cap $3.97B). The key difference: Mattel Inc is far larger — about 300.8× BioNano Genomics Inc's market cap. Which is the better fit depends on your goals.
| BNGO | MAT | |
|---|---|---|
Market Cap | $13.20M | $3.97B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.92 | $22.16 |
52-Week Low | $1.09 | $13.05 |
Enterprise Value | $15.81M | $5.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Mattel (MAT) trades at $13.84, up 3.83% today, with a bullish technical signal and strong valuation metrics including a P/E of 8.86 and P/S of 0.81. Recent earnings showed a Q1 2026 beat but Q3-Q4 2025 misses, while revenue stability around $5.4B supports a 9.27% net margin. News highlights include Comic-Con exclusives and a Barbie-Dunkin' collaboration, though cash flow turned negative in 2025.
The stock presents value with low multiples and 50% analyst buy ratings, targeting $14.60 consensus. Risks include volatile earnings, debt load, and activist pressure for a sale. Upside depends on brand execution offsetting consumer spending sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →
